Nathan Gaul
GlaxoSmithKline (United States) · 3 works · 675 citations · h-index 2
Top works
- Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity
- Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development
- Abstract 5418: Rapid LDH5 inhibition reverses malignant metabolic phenotype and impairs survival of hepatocellular carcinoma cells .